Abstract
Objective To study the posibility of hepatocellular carcinoma HCC) vaccines from dendritic cells (DCs) stimulated with alpha fetal protein (AFP) peptides or Lenti-AFP for hepatoceHular carcinoma (HCC) immunotherapy.Methods We created a lentivirus expressing AFP (Lenti-AFP) and AFP peptides liver tumor vaccines,and antitumor activity of AFP-specific HCC vaccines for tumor growth and related cytokines [interleukin (IL)-2,interferon (IFN)-γ,IL-10,tumor necrosis factor (TNF)-αt,perforin and granzyme B,FasL) were observed in 4 groups (Lenti-AFP,AFP1,AFP542 and control) in vivo.Results The AFP-specific tumor vaccines could efficiently kill HCC cells in vivo.The tumor diameter in control group was (12.28 ±3.49) cm,and that in treatment groups was (7.03 ±2.78),(11.00 ±2.57),(8.87 ±3.49) cm,respectively (FD =6.13,P<0.01).The tumor weight in control group was (0.478 ± 0.225) g,and that in treatment groups was (0.398 ± 0.125),(0.298 ± 0.099),(0.228 ±0.132) g respectively (Fw =5.38,P < 0.01).The levels of IL-2,IFN-γ,TNF-α,perforin and granzyme B were increased to varying degrees,and those of IL-10 were significantly reduced in the treatment groups (P <0.05).Conclusion AFP-specific CD8 +/CD4 + T cells tumor vaccines which were activated by either Lenti-AFP-engineered or AFP peptide-pulsed DCs have obviously antitumor activity in vivo.This study provides new insight into the design of HCC immunotherapy. Key words: Carcinoma,hepatocellular; Alpha-fetal protein; Dendritic cell
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.